IBOGF (Universal Ibogaine) Debt-to-Equity: 9.43 (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Universal Ibogaine Debt-to-Equity?

Universal Ibogaine IBOGF Debt-to-Equity is 9.43 as of Apr. 2025.

Universal Ibogaine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2025 was $0.61 Mil. Universal Ibogaine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2025 was $1.23 Mil. Universal Ibogaine's Total Stockholders Equity for the quarter that ended in Apr. 2025 was $0.20 Mil. Universal Ibogaine's debt to equity for the quarter that ended in Apr. 2025 was 9.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Universal Ibogaine's Debt-to-Equity or its related term are showing as below:

IBOGF's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Universal Ibogaine  (OTCPK:IBOGF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Universal Ibogaine Debt-to-Equity Related Terms

Universal Ibogaine Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Debt-to-Equity Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Debt-to-Equity
Get a 7-Day Free Trial 0.00 -16.00 0.44 1.59 2.68

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 2.68 4.06 7.59 9.43

IBOGF vs LABT, CALC, LNAI: Debt-to-Equity Comparison

For the Biotechnology subindustry, Universal Ibogaine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Debt-to-Equity falls into.


Universal Ibogaine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Universal Ibogaine's Debt to Equity Ratio for the fiscal year that ended in Jul. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.094 + 1.84) / 0.723
=2.67

Universal Ibogaine's Debt to Equity Ratio for the quarter that ended in Apr. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.607 + 1.232) / 0.195
=9.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 9.43 mean?
Universal Ibogaine (IBOGF) has a Debt-to-Equity of 9.43 as of Apr. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Universal Ibogaine and its competitors.
Is Universal Ibogaine's Debt-to-Equity too high?
Universal Ibogaine's current Debt-to-Equity is 9.43. The Biotechnology industry median Debt-to-Equity is 0.16. Universal Ibogaine's value of 9.43 is 5793.8% above this industry median.
How does Universal Ibogaine's Debt-to-Equity compare to LABT and CALC?
Universal Ibogaine's Debt-to-Equity of 9.43 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. Universal Ibogaine's value of 9.43 is 5793.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universal Ibogaine's current Debt-to-Equity of 9.43 is 5793.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Universal Ibogaine and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universal Ibogaine's current Debt-to-Equity is 9.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Debt-to-Equity of 9.43. The current Debt-to-Equity is 9.43 and 5793.8% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Debt-to-Equity is 9.43 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.